Not playing with a full DEC: Why development and evaluation committee methods for appraising new drugs may be inadequate

British Medical Journal

Volumn 318, Issue 7196, 1999, Pages 1480-1482

  Freemantle, Nick ^a   Mason, James ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG APPROVAL; DRUG SCREENING; HEALTH CARE QUALITY; LICENSING; MEDICAL AUDIT; PHARMACOECONOMICS; PRIORITY JOURNAL; SHORT SURVEY; TREATMENT OUTCOME;

EID: 0033614684     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.318.7196.1480     Document Type: Short Survey

References (11)

1. 1 NHS Executive. A first class service: quality in the new NHS. London: Stationery Office, 1998.
2. 2 Freemantle N, Barbour R, Johnson R, Marchment M, Kennedy A. The use of statins: a case of misleading priorities? BMJ 1997;315:826-8.
3. 3 Eccles M, Freemantle N, Mason JM for the North of England Guidelines Development Group. The choice of antidepressants for depression in primary care. Fam Pract (in press).
4. 4 Roberts I. An amnesty for unpublished trials: one year on, many trials are unregistered and the amnesty remains open. BMJ 1998;317:763-4.
5. 5 Eccles M, Freemantle N, Mason JM, for the North of England ACE-Inhibitor Guideline Development Group. North of England evidence based development project: guideline for angiotensin converting enzyme inhibitors in primary care management of adults with symptomatic heart failure. BMJ 1998;316:1369-75.
6. 6 Mason JM, Drummond MF. Reporting guidelines for economic studies. Health Econ 1995;4:85-94.
7. 7 Wessex Development and Evaluation Committee. Donepezil in the treatment of mild to moderate sentle demenia of the Alzheimer type (SDAT). Bristol: NHS Research and Development, 1997, (Report No 69.)
8. 8 Eccles M, Clarke J, Livingstone M, Freemantle N, Mason J. North of England evidence based guidelines development project: guideline for the primary care management of dementia. BMJ 1998;317:802-8.
9. 9 Rogers SL, Friedhoff LT, and the Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre randomised, double-blind, placebo controlled trial. Dementia 1996;7:293-303.
10. 10 Development and Evaluation Committee. The use of olanzapine as a first and second choice treatment in schizophrenia. Bristol: NHS Research and Development. 1998. (Report No 84.)
11. 11 Eccles M, Freemantle N, Mason J. North of England evidence based guidelines development project: methods of developing guidelines for efficient drug use in primary care. BMJ 1998;316:1232-5. (Accepted 10 February 1999)